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Background: The purpose of this study was to evaluate the real-world use, efficacy, and safety 
of one or more dexamethasone intravitreal implant(s) 0.7 mg (DEX implant) in patients with 
macular edema (ME).
Methods: This was a retrospective cohort study of patients with ME secondary to retinal disease 
treated at ten Canadian retina practices, including one uveitis center. Best-corrected visual acu-
ity (BCVA), central retinal thickness (CRT), intraocular pressure (IOP), glaucoma and cataract 
surgery, and safety data were collected from the medical charts of patients with 3 months of 
follow-up after the initial DEX implant.
Results: One hundred and one patient charts yielded data on 120 study eyes, including diag-
noses of diabetic ME (DME) (n=34), retinal vein occlusion (RVO, n=30; branch in 19 and 
central in 11), and uveitis (n=23). Patients had a mean age of 60.9 years, and 73.3% of the study 
eyes had ME for a duration of 12 months prior to DEX implant injection(s). Baseline mean 
(± standard error) BCVA was 0.63±0.03 logMAR (20/86 Snellen equivalents) and mean CRT 
was 474.4±18.2 μm. The mean number of DEX implant injections was 1.7±0.1 in all study 
eyes; 44.2% of eyes had repeat DEX implant injections (reinjection interval 2.3–4.9 months). 
The greatest mean peak changes in BCVA lines of vision occurred in study eyes with uveitis 
(3.3±0.6, P0.0001), followed by RVO (1.3±0.5, P0.01) and DME (0.7±0.5, P0.05). 
Significant decreases in CRT were observed: -255.6±43.6 μm for uveitis, -190.9±23.5 μm for 
DME, and -160.7±39.6 μm for RVO (P0.0001 for all cohorts). IOP increases of 10 mmHg 
occurred in 20.6%, 24.1%, and 22.7% of DME, RVO, and uveitis study eyes, respectively. 
IOP-lowering medication was initiated in 29.4%, 16.7%, and 8.7% of DME, RVO, and uveitis 
study eyes, respectively. Glaucoma surgery was performed in 1.7% of all study eyes and cataract 
surgery in 29.8% of all phakic study eyes receiving DEX implant(s).
Conclusion: DEX implant(s) alone or combined with other treatments and/or procedures 
resulted in functional and anatomic improvements in long-standing ME associated with retinal 
disease.
Keywords: diabetic macular edema, posterior segment inflammatory disease, retinal vein 
occlusion, registry, sustained-release dexamethasone implant, Ozurdex®
Introduction
Macular edema (ME) most often results from retinal diseases such as diabetic 
retinopathy, retinal vein occlusion (RVO), exudative age-related macular degeneration, 
and uveitis, and commonly presents with symptoms of blurred or reduced central vision. 
Research into the pathophysiology of ME has led to a greater understanding of the 
underlying mechanisms and the role of inflammatory mediators that facilitate cellular 
damage, leading to accumulation of fluid within the retina.1,2 The anti-inflammatory, 
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antiangiogenic, and antipermeability effects of corticoster-
oids counteract three key pathologic processes involved in 
the development of ME.2,3 However, the efficacy of cor-
ticosteroids is greatly affected by the route of administra-
tion. Direct intravitreal delivery of corticosteroids, which 
bypasses the blood–retinal barrier, results in a high local 
drug concentration and improved systemic safety.3 The abil-
ity to safely deliver therapeutic drug levels to the posterior 
segment of the eye without the need for frequent redosing 
remains a challenge with the currently available treatment 
options for ME.
Dexamethasone (DEX) is a corticosteroid with anti- 
inflammatory activity up to six fold greater than prednisolone 
or triamcinolone, 25-fold greater than hydrocortisone, and 
similar to fluocinolone acetonide.4 Injection of DEX into 
the vitreous humor has been shown to produce high drug 
concentrations with low toxicity; however, the half-life of 
DEX following intravitreal injection is short (approximately 
3 hours), limiting its usefulness.5–7 The 0.7 mg intravitreal 
DEX implant (Ozurdex®, Allergan, Inc., Irvine, CA, USA) 
is a biodegradable solid polymer drug delivery system.8 
A single-use applicator with a 22-gauge needle that leaves 
a sutureless self-sealing wound is used to place the DEX 
implant into the vitreous cavity.9 The sustained-release 
formulation was designed to release DEX from the implant 
for up to 6 months,10 as the poly(D,L-lactide-co-glycolide) 
polymer matrix (Novadur®, Allergan, Inc.) degrades into 
lactic acid and glycolic acid, and then metabolizes to water 
and carbon dioxide. Therefore, sequential DEX implants can 
be safely administered as an office-based procedure without 
the need for surgical removal.
In an earlier study, DEX implant treatment of eyes with 
persistent ME secondary to various retinal diseases produced 
significant improvements in best-corrected visual acuity 
(BCVA), macular thickness, and fluorescein leakage when 
compared with no treatment.11 The efficacy of the DEX 
implant for ME following branch or central RVO (BRVO, 
CRVO) was established in two identical, prospective, multi-
center, randomized, sham-controlled, 6-month clinical trials, 
in which treatment with a single DEX 0.7 mg implant injec-
tion significantly improved BCVA and anatomic outcomes 
compared with sham treatment.12,13 In another prospective, 
multicenter, randomized, sham-controlled, 6-month clinical 
trial, treatment with a single DEX implant for noninfectious 
intermediate or posterior uveitis resulted in a significant pro-
portion of study eyes demonstrating complete resolution of 
vitreous haze and a significant percentage achieving three or 
more lines of vision gain throughout the entire study period.14 
The DEX implant is administered with the intention to treat 
ME associated with uveitis and does not control the underly-
ing disease. The sustained release of DEX into the vitreous 
space provided by the DEX implant has also been shown to 
control ME over several months in vitrectomized eyes.15,16
Elevations in intraocular pressure (IOP) and cataract for-
mation are common concerns with intravitreal corticosteroid 
injections. In the RVO and uveitis DEX implant phase III tri-
als, a transient increase in IOP was observed (typically peak-
ing 60 days after DEX implant injection), and no more than 
24% of eyes required treatment with topical IOP-lowering 
medication. Six months after a single DEX implant was 
injected, no significant increases in cataract adverse events 
were observed.12,14 However, a significant increase in cata-
ract (7.3%–29.8%) was seen following retreatment with the 
DEX implant.13 Reported adverse event rates for cataract and 
cataract surgery following an average of five DEX implants 
over a 3-year period for the treatment of diabetic ME (DME) 
were 67.9% and 59.2%, respectively.17
Several retrospective case series conducted in the USA 
and Europe have been published evaluating the use of DEX 
implants for the treatment of ME, particularly in patients with 
RVO18–20 but also in DME21,22 and uveitis.23 In Canada, at the 
time the present study was conducted, the DEX implant was 
approved only for treatment of ME following CRVO, and 
for treatment of noninfectious uveitis affecting the posterior 
segment of the eye,24 and there was a lack of observational 
studies assessing the efficacy and safety of DEX implants 
in the clinical setting. We conducted a retrospective study 
to explore the use of DEX implant by Canadian retina and 
uveitis specialists in a real-world clinical practice setting. The 
objectives of this study were to describe the demographics 
and ophthalmic medical history of patients with ME treated 
with the DEX implant, to assess treatment patterns for use of 
the DEX implant, and to evaluate the functional, anatomic, 
and safety outcomes after one or more DEX implant injec-
tions in patients with ME.
Materials and methods
study design
This was a multicenter, retrospective, open-label, exploratory 
chart review of data collected from patients with ME treated 
with one or more DEX implants (0.7 mg) at ten Canadian 
retina practices, including one uveitis center (ClinicalTrials.
gov identifier NCT01805323). The study was conducted 
according to the International Conference on Harmonisation 
Good Clinical Practice guidelines and all applicable regula-
tory authority requirements and national laws. The protocol 
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was reviewed and approved by the institutional review 
board or independent ethics committee of each site prior to 
commencing the study. Patients enrolled in the study were 
assigned an identification number (consisting of a site and 
a patient number), and no patient-identifiable information 
was collected.
eligibility criteria and data collection
Medical records were included in the study if the patient met 
all the following criteria: had a diagnosis of retinal disease 
involving ME in the study eye(s); received at least one DEX 
implant and had follow-up data for a minimum duration of 
3 months (12±2 weeks) after the first injection; had data col-
lected from December 1, 2010 through December 1, 2012 
inclusive; and had signed an informed consent form prior to 
first collection of study data. Patient charts were excluded if 
“no” was the answer to any of the four inclusion criteria. 
Data were collected from the patient charts for three types 
of visits (Table S1): visit 1 – medical history visit prior to 
DEX implant injection (screening visit); visit 2 – baseline 
first injection visit or subsequent DEX implant injection visits 
(day 1); visit 3 – post-injection follow-up visits from 2 to up 
to 26 weeks after each DEX implant injection or until the 
next DEX implant injection. No data were collected beyond 
26 weeks (6 months) for patients who were still within the 
study interval but were not scheduled to receive additional 
DEX implants. Any ocular procedures performed following 
DEX implant injection (eg, laser photocoagulation, cata-
ract surgery) were captured from records of post-injection 
follow-up visits.
Efficacy and safety assessments
Efficacy was measured by calculating the peak mean change 
in BCVA and central retinal thickness (CRT) using optical 
coherence tomography (OCT) from baseline to 2–26 weeks 
following the last DEX implant injection. OCT instruments 
used at the ten study sites included Cirrus HD-OCT (n=5; 
Carl Zeiss Meditec Inc, Dublin, CA, USA); Spectralis (n=3; 
Heidelberg Engineering Inc, Heidelberg, Germany); RTVue 
(n=1; Optovue, Fremont, CA, USA); and 3D OCT-2000 
(n=1; Topcon Medical Systems Inc, Oakland, NJ, USA). 
Peak BCVA line change from baseline was calculated by 
converting logMAR values to number of lines as described 
by Holladay et al.25 A clinically significant decrease in BCVA 
(defined as a reduction of 10 letters compared with base-
line), a clinically significant increase in CRT (defined as an 
increase of 50 μm compared with baseline), or a failure 
of the DEX implant to produce the expected/intended effect 
leading to an adverse outcome for the patient in the opinion 
of the investigator were to be reported as an adverse event.
Safety was assessed by monitoring changes in IOP, use 
of IOP-lowering medications, incidence of glaucoma and 
cataract surgery, and investigator-reported adverse events 
such as injection-related events. IOP elevations of 5 mmHg 
from baseline were considered to be corticosteroid-related 
responses and reported as adverse events. All adverse event 
terms recorded in patient medical charts were mapped to 
Preferred Terms and System Organ Classes using the Medical 
Dictionary for Regulatory Activities. 
Data analysis and statistical methods
Data were retrospectively collected from patients’ medical 
charts. Given the exploratory nature of the study, most analyses 
were descriptive for treatment patterns and safety outcomes 
with the DEX implant and concurrent therapies. Efficacy 
outcomes after DEX implant injection are presented by retinal 
disease subgroups in cohorts that had sufficient data for analy-
sis; subgroup analyses of phakic and pseudophakic and non-
vitrectomized and vitrectomized eyes were also performed.
Continuous variables were summarized using descriptive 
statistics, including sample size, mean, standard error (SE), 
median, minimum, and maximum. Categorical variables 
were summarized by frequency and percentage tables. Peak 
mean change in BCVA and CRT analyses only included 
patients with observations available for the last DEX implant 
injection from 2 to 26 weeks with a minimum follow-up 
of 12±2 weeks; the 95% confidence interval and statistical 
significance were analyzed using a generalized estimating 
equations model with a correlation structure. The nature and 
frequency of adverse events were tabulated throughout the 
study and summarized using descriptive statistics. Use of 
and access to data were supervised by a scientific advisory 
committee and Allergan Inc.
Results
Baseline demographics
In all, 101 patient charts were eligible for inclusion in the 
study with a total of 120 study eyes for analysis (Table 1). No 
medical charts from patients who met the eligibility criteria 
were excluded from the analysis. Retinal disease subgroups 
with a sufficient number of study eyes for meaningful analy-
sis of functional and anatomic outcomes (20) included 
DME, RVO (BRVO and CRVO), and uveitis. Cohorts with 
other ocular diagnoses were not large enough for separate 
analysis (Table 2), but were combined in the all eyes study 
group. The overall patient age (mean ± standard deviation) 
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was 60.9±14.8 years. Males comprised two-thirds of the 
study population (65.3%), and the majority of patients were 
Caucasian (77.2%). Systemic hypertension was the most com-
mon comorbid condition in the study population (55.4%). 
DEX implants were most frequently used to treat study 
eyes with an indication of DME (28.3%), followed by RVO 
(25.0%) and uveitis (19.2%). Prior to the first DEX implant 
injection, 73.3% of all eyes had persistent ME for a period 
of 12 months or more (Table 3). Mean (± SE) BCVA, CRT, 
and IOP were 0.63±0.03 logMAR (20/86 Snellen equiva-
lents), 474.4±18.2 μm, and 14.4±0.4 mmHg, respectively, 
at baseline. Overall, 25.0% of the study eyes had a history of 
steroid response, defined as an IOP elevation of 5 mmHg 
following prior topical or intravitreal steroid exposure. 
The uveitis cohort had the greatest proportion (34.8%) of 
study eyes known to have a history of steroid response.
Prior treatments and ocular procedures
The most commonly reported previous treatments in study 
eyes with DME and RVO were intravitreal bevacizumab 
(47.1% and 36.7%, respectively) and intravitreal triamci-
nolone acetonide (IVTA, 38.2% and 30.0%, respectively, 
Table 3). Study eyes with uveitis were most commonly 
treated with IVTA (65.2%) and sub-Tenon’s triamcinolone 
acetonide (43.5%); systemic prednisone (43.5%), mycophe-
nolate mofetil (26.1%), methotrexate (30.4%), cyclosporine 
(13.0%), and methylprednisolone (8.7%) had also been 
prescribed prior to DEX implant. 
Prior cataract surgery was particularly prevalent in eyes 
with a diagnosis of DME (67.6%). Prior glaucoma surgery 
was most frequently reported in the uveitis cohort (17.4%). 
Before administration of the first DEX implant injection, 
laser surgery (focal/grid or panretinal photocoagulation) 
and vitrectomy had been performed frequently in eyes with 
DME (55.9% for each), and vitrectomy was also commonly 
reported in eyes with RVO (40.0%).
DeX implant treatment patterns
The most frequently reported rationales for choosing DEX 
implant therapy by the Canadian physicians participating in 
this study were to improve visual acuity, to decrease ME, and 
to rescue eyes that had proved to be nonresponsive to other 
available therapies. The mean (± SE) number of injections 
for study eyes with DME, RVO, and uveitis was 1.6±0.1, 
1.7±0.1, and 1.7±0.2, respectively. The mean (± SE) time 
Table 1 Baseline demographics of patients treated with intravitreal dexamethasone implant injection
All patients 
(N=101)
DME
(n=24)
RVO
(n=29)a
Uveitis
(n=20)
age, years
Mean (sD) 60.9 (14.8) 64.0 (11.2) 64.4 (12.0) 49.8 (16.7)
range 11–89 36–83 31–81 11–79
sex, % (n)
Female 34.7 (35) 33.3 (8) 17.2 (5) 50.0 (10)
Male 65.3 (66) 66.7 (16) 82.8 (24) 50.0 (10)
race, % (n)
asian 6.9 (7) 8.3 (2) 10.3 (3) 0.0 (0)
Black 3.0 (3) 4.2 (1) 0.0 (0) 10.0 (2)
hispanic 2.0 (2) 0.0 (0) 6.9 (2) 0.0 (0)
Other 10.9 (11) 0.0 (0) 10.3 (3) 5.0 (1)
White 77.2 (78) 87.5 (21) 72.4 (21) 85.0 (17)
selected baseline comorbidities, % (n)
Diabetes mellitus 27.7 (28) 100 (24) 13.8 (4) 0.0 (0)
hypertension 55.4 (56) 91.7 (22) 72.4 (21) 30.0 (6)
Note:  arVO cohort included branch (n=19) and central (n=11) forms. 
Abbreviations: DMe, diabetic macular edema; rVO, retinal vein occlusion; sD, standard deviation.
Table 2 Ocular diagnoses other than diabetic macular edema, 
retinal vein occlusion, and uveitis in study eyes included in the all 
eyes cohort
Ocular diagnosis Study eyes (n)
Coat’s disease 1
Cystoid macular edema 1
eales’ disease 1
epiretinal membrane 7
idiopathic cystoid macular edema 2
irvine-gass syndrome 3
Macular hole 1
Macular telangiectasia 5
neovascular age-related macular degeneration 2
Post-laser tear 1
retinal angioma 1
retinal detachment 5
retinal necrosis syndrome 2
Vitreomacular traction 1
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to the first and second DEX implant reinjection intervals 
(ie, second and third DEX implants) was longest in DME 
(5.8±0.5 months and 5.6±1.0 months, respectively) and RVO 
(4.9±0.3 months and 7.2±2.3 months, respectively) study 
eyes. The uveitis cohort had the shortest first and second 
DEX implant reinjection intervals (4.7±0.3 months and 
3.4±0.4 months, respectively).
Concomitant treatments and procedures
In the DME, RVO, and uveitis cohorts, repeat DEX implant 
injections were administered to 44.2%, 50.0%, and 43.5% 
of study eyes, respectively, and adjunctive treatments and/or 
procedures were administered to 41.2%, 26.7%, and 78.3% 
of study eyes, respectively (Table 4). The most common 
adjunctive intravitreal treatments administered with DEX 
implants among DME, RVO, and uveitis study eyes were 
bevacizumab (8.8%, 10.0%, and 13.0%, respectively) 
and IVTA (20.6%, 13.3%, and 4.3%, respectively). 
Systemic treatments were primarily administered to 
patients with a diagnosis of uveitis, with the most common 
systemic therapy in this group being mycophenolate 
mofetil (47.8%). 
Table 3 study eye characteristics and treatments and procedures administered prior to intravitreal dexamethasone implant injection
Baseline parameter All eyes
(N=120)
DME
(n=34)
RVO
(n=30)
Uveitis
(n=23)
Study eye characteristics
Baseline lens status, % (n)
aphakic 0.8 (1) 0.0 (0) 0.0 (0) 0.0 (0)
Phakic 39.2 (47) 32.4 (11) 43.3 (13) 47.8 (11)
Pseudophakic 60.0 (72) 67.6 (23) 56.7 (17) 52.2 (12)
Macular edema prior to first injection, % (n)
3 months 5.8 (7) 0.0 (0) 6.7 (2) 8.7 (2)
3 to 12 months 15.8 (19) 5.9 (2) 13.3 (4) 30.4 (7)
12 months 73.3 (88) 94.1 (32) 70.0 (21) 56.5 (13)
Unknown duration 5.0 (6) 0.0 (0) 10.0 (3) 4.3 (1)
Visual acuity
logMar (mean ± se) 0.63±0.03 0.60±0.07 0.64±0.06 0.71±0.07
snellen equivalent 20/86 20/81 20/88 20/102
Central retinal thickness, μm (mean ± se) 474.4±18.2 450.4±26.0 434.8±37.4 517.2±40.3
range, μm 180–1,035 180–690 218–866 285–872
intraocular pressure, mmhg (mean ± se) 14.4±0.4 15.5±0.9 15.6±0.7 12.3±0.8
history of steroid response, % (n) 25.0 (30) 29.4 (10) 16.7 (5) 34.8 (8)
Continuing prior iOP-lowering medication, % (n) 21.7 (26) 29.4 (10) 23.3 (7) 21.7 (5)
Prior treatments and procedures
injections, % (n)
intravitreal bevacizumab 31.7 (38) 47.1 (16) 36.7 (11) 17.4 (4)
intravitreal ranibizumab 10.8 (13) 8.8 (3) 3.3 (1) 8.7 (2)
intravitreal triamcinolone acetonide 42.5 (51) 38.2 (13) 30.0 (9) 65.2 (15)
sub-Tenon’s triamcinolone acetonide 20.8 (25) 5.9 (2) 10.0 (3) 43.5 (10)
systemic medications, % (n)
Cyclosporine 2.5 (3) 0.0 (0) 0.0 (0) 13.0 (3)
Methotrexate 5.8 (7) 0.0 (0) 0.0 (0) 30.4 (7)
Methylprednisolone 1.7 (2) 0.0 (0) 0.0 (0) 8.7 (2)
Mycophenolate mofetil 5.8 (7) 0.0 (0) 0.0 (0) 26.1 (6)
Prednisone 10.0 (12) 0.0 (0) 0.0 (0) 43.5 (10)
surgical interventions, % (n)
Cataract surgery 60.0 (72) 67.6 (23) 56.7 (17) 52.2 (12)
Focal or grid laser 30.0 (36) 55.9 (19) 36.7 (11) 0.0 (0)
glaucoma surgery 8.3 (10) 11.8 (4) 6.7 (2) 17.4 (4)
Membrane peel 14.2 (17) 17.6 (6) 16.7 (5) 13.0 (3)
Panretinal photocoagulation 22.5 (27) 55.9 (19) 23.3 (7) 0.0 (0)
Photodynamic therapy with verteporfin 2.5 (3) 0.0 (0) 0.0 (0) 0.0 (0)
Pneumatic retinopexy 2.5 (3) 2.9 (1) 3.3 (1) 0.0 (0)
scleral buckling 2.5 (3) 0.0 (0) 0.0 (0) 4.3 (1)
Vitrectomy 47.5 (57) 55.9 (19) 40.0 (12) 30.4 (7)
Abbreviations: DMe, diabetic macular edema; iOP, intraocular pressure; rVO, retinal vein occlusion; se, standard error.
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Few surgical procedures were performed during the 
study period. Vitrectomy was the most commonly reported 
procedure in study eyes with DME (11.8%) and vitrectomy 
with membrane peeling was most prevalent in study eyes 
with DME (8.8%). Focal/grid laser was most prevalent in 
study eyes with RVO (10.0%) and DME (5.9%). One eye 
with uveitis was switched to a fluocinolone acetonide implant 
(Retisert®, Bausch & Lomb Inc, Rochester, NY, USA) by a 
clinician who believed a longer-acting intraocular steroid was 
needed. This same eye underwent prophylactic tube-shunt 
glaucoma surgery at conclusion of surgical placement of the 
fluocinolone acetonide implant.
Efficacy of DEX injections in DME, RVO, 
and uveitis cohorts
The greatest peak mean line gains from baseline after DEX 
implant injection were observed in study eyes with uveitis 
(P0.0001), followed by RVO (P0.01). Significant peak 
mean line gains were also observed in subgroups of non-
vitrectomized and vitrectomized eyes with uveitis and non-
vitrectomized eyes with RVO (Figure 1). For study eyes 
with DME, average peak gains in lines of vision were not 
statistically significant compared with baseline for all eyes 
or for non-vitrectomized and vitrectomized eyes (Figure 1). 
When analyzed by lens status at baseline, in the DME cohort, 
a peak mean loss of 0.6±0.6 lines in phakic eyes and a statisti-
cally significant peak mean gain of 1.4±0.5 lines (P0.05) 
in pseudophakic eyes was reported.
Study eyes with a diagnosis of uveitis had the highest 
proportion of eyes gaining one or more lines of vision (81.0%, 
mean baseline vision, 0.76±0.08 logMAR; 20/115 Snellen 
equivalents), followed by RVO (44.4%, mean baseline vision, 
0.69±0.08 logMAR; 20/97 Snellen equivalents) and DME 
(37.5%, mean baseline vision, 0.80±0.09 logMAR; 20/125 
Table 4 Medications and procedures used adjunctively with intravitreal dexamethasone implant therapy
Treatment or procedure All eyes
(N=120)
DME
(n=34)
RVO
(n=30)
Uveitis
(n=23)
injections, % (n)
intravitreal bevacizumab 7.5 (9) 8.8 (3) 10.0 (3) 13.0 (3)
intravitreal dexamethasone implant 44.2 (53) 44.1 (15) 50.0 (15) 43.5 (10)
intravitreal ranibizumab 1.7 (2) 2.9 (1) 3.3 (1) 0.0 (0)
intravitreal triamcinolone acetonide 14.2 (17) 20.6 (7) 13.3 (4) 4.3 (1)
sub-Tenon’s triamcinolone acetonide 1.7 (2) 0.0 (0) 0.0 (0) 8.7 (2)
systemic medications, % (n)
Cyclosporine 4.2 (5) 0.0 (0) 0.0 (0) 17.4 (4)
Methotrexate 3.3 (4) 0.0 (0) 0.0 (0) 17.4 (4)
Mycophenolate mofetil 10.0 (12) 0.0 (0) 0.0 (0) 47.8 (11)
Prednisone 3.3 (4) 0.0 (0) 0.0 (0) 17.4 (4)
laser or surgical interventions, % (n)
Fluocinolone acetonide implant 0.8 (1) 0.0 (0) 0.0 (0) 4.3 (1)
Focal or grid laser 4.2 (5) 5.9 (2) 10.0 (3) 0.0 (0)
laser barricade 1.7 (2) 0.0 (0) 0.0 (0) 8.7 (2)
Membrane peel 4.2 (5) 8.8 (3) 3.3 (1) 4.3 (1)
Panretinal photocoagulation 0.8 (1) 0.0 (0) 0.0 (0) 0.0 (0)
Vitrectomy 8.3 (10) 11.8 (4) 3.3 (1) 8.7 (2)
no treatment/procedure other than DeX implant, % (n) 60.0 (72) 58.8 (20) 73.3 (22) 21.7 (5)
Abbreviations: DeX implant, intravitreal dexamethasone implant; DMe, diabetic macular edema; rVO, retinal vein occlusion.
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Figure 1 Peak mean change in BCVa (snellen line equivalent) from baseline at 
2–26 weeks after the last DeX implant injection.
Notes: *P0.05, **P0.01, ***P0.001, ****P0.0001 for intragroup comparison 
with corresponding baseline values prior to treatment with the DeX implant. Missing 
data points resulted from lack of baseline visual acuity in the medical chart or lack of 
follow-up at a minimum of 12±2 weeks after the last DeX implant. n represents the 
total number of eyes in each group, and n represents number of eyes with follow-
up data for analysis. as vision was analyzed after the last injection, patients initially 
treated with the DeX implant and who received subsequent reinjections may not 
have had sufficient follow-up data in their medical charts for analysis purposes. 
Abbreviations: BCVa, best-corrected visual acuity; DeX, intravitreal 
dexamethasone; DMe, diabetic macular edema; rVO, retinal vein occlusion; se, 
standard error.
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Snellen equivalents, Figure 2A). A similar pattern for two or 
more and three or more lines of vision gains was observed fol-
lowing one to three DEX implant injections, with the highest 
proportions achieved by uveitis study eyes (Figure 2B and C). 
The proportions of DME, RVO, and uveitis study eyes that 
had ME for a duration of 12 months and had 0 or fewer 
lines of vision change from baseline were 46.7% (mean base-
line vision, 0.58±0.08 logMAR; 20/76 Snellen equivalents), 
42.1% (mean baseline vision, 0.57±0.12 logMAR; 20/74 
Snellen equivalents); and 9.1% (mean baseline vision, 0.54 
logMAR; 20/70 Snellen equivalents), respectively.
Study eyes with uveitis demonstrated the greatest 
decrease in CRT, followed by study eyes with DME and 
RVO (P0.0001 for each group compared with baseline, 
Figure 3). In the DME, RVO, and uveitis cohorts, significant 
decreases in CRT were observed in both non-vitrectomized 
and vitrectomized study eyes (Figure 3). The percentage 
of uveitis eyes with ME (ie, CRT 300 μm) at baseline 
that showed both a reduction in CRT and improved vision 
(ie, 0 lines gained) following treatment with DEX implant 
was 66.7% (14/21). The baseline mean (± SE) CRT and vision 
for these eyes were 546.3±38.8 μm and 0.8±0.1 logMAR 
(20/128 Snellen equivalents), respectively. Following treat-
ment with the DEX implant, the mean (± SE) peak improve-
ment in CRT was -274.3±42.3 μm and the corresponding 
vision improved +4.0 lines for a final mean (± SE) vision of 
0.4±0.1 logMAR (20/51 Snellen equivalents). Figure 4 shows 
OCT images from representative DME, BRVO, and uveitis 
cases following treatment with the DEX implant.
safety of intravitreal DeX implant 
injections
A total of 35 treatment-related adverse events were reported 
following the first DEX implant in patients with a diagnosis 
of DME (33.3%; 8/24), RVO (37.9%; 11/29), and uveitis 
(25.0%; 5/20). The most commonly reported adverse event 
was increased IOP, with a total of 24 events for DME 
(25.0%; 6/24), RVO (27.6%; 8/29), and uveitis (10.0%; 2/20) 
patients (Table 5). Other treatment-related adverse events 
occurring in 1% of patients were subcapsular cataracts 
and retinal detachments (5.0%; 1/20 each in uveitis patients) 
and reduced visual acuity (6.9%; 2/29 in RVO patients). The 
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Figure 2 Proportion of study eyes with gains of 1 or more (A), 2 or more (B), and 3 or more (C) BCVA lines of vision after the first, second, and third DEX implant 
injection.
Notes: Data for the proportion of eyes with gains of 1 or more, 2 or more, and 3 or more lines of vision was calculated at any available study visit. For each group, 
n represents the total number of eyes available for analysis, and n represents the number of study eyes achieving 1, 2, or 3 lines of vision gain. 
Abbreviations: BCVa, best-corrected visual acuity; DeX, intravitreal dexamethasone; DMe, diabetic macular edema; rVO, retinal vein occlusion.
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eye that developed a retinal detachment underwent surgical 
repair and treatment with the DEX implant was continued. 
Endophthalmitis was reported as a serious adverse event 
related to DEX implant treatment in a patient with BRVO, 
and a uveitis flare was reported as a serious adverse event 
unrelated to DEX implant treatment in a patient with 
uveitis. The lone case of endophthalmitis resolved follow-
ing treatment with intravitreal injection of vancomycin, 
and treatment with the DEX implant was discontinued. 
No serious adverse events were reported among patients 
diagnosed with DME.
The proportion of eyes in the DME, RVO, and uveitis 
subgroups with IOP increases of at least 10 mmHg ranged 
from 20.6% to 24.1% (Figure 5). Those with an absolute 
IOP reading of 25 mmHg or 35 mmHg recorded at any 
follow-up visit after DEX implant(s) ranged from 17.4% to 
26.7% and from 2.9% to 6.7%, respectively (Figure 5). The 
proportions of DME, RVO, and uveitis study eyes requir-
ing topical IOP-lowering therapy at any point following 
treatment with the DEX implant in the study were 29.4%, 
16.7%, and 8.7%, respectively (Figure 6). Cases of new 
onset elevated IOP were reported in 70.0% of DME, 80.0% 
of RVO, and 50.0% of uveitis study eyes. In this set of eyes, 
only one DME eye with a history of steroid response had 
new onset elevated IOP.
The proportions of DME, RVO, and uveitis eyes that 
had a history of steroid response and also experienced an 
IOP increase of at least 10 mmHg following DEX implant 
treatment(s) were 40.0%, 20.0%, and 37.5%, respectively. 
The proportions of DME, RVO, and uveitis eyes that had a 
history of steroid response and also presented at follow-up 
visits with absolute IOP readings 25 mmHg were 20.0%, 
20.0%, and 37.5%, respectively. Only study eyes with uveitis 
(12.5%) and other ocular diagnoses (28.6%; not including 
???
???
????
???
????
???
????
???
???
????
??
???
????
???
??µ?
?
????????
???
??????
??????
??????
??????
??????????? ??????????? ??????????? ??????????? ??????????? ?????????? ??????????? ??????????? ???????????
????? ????? ????? ?????
??
???? ???? ????
????
???? ????
????
???
????? ????? ????? ?????? ???????
???????? ????????????????? ?????????????
Figure 3 Peak mean change in CrT from baseline at 2–26 weeks after the last DeX 
implant injection.
Notes: **P0.01, ***P0.001, ****P0.0001 for intragroup comparison with 
corresponding baseline values prior to treatment with DeX implants. Missing data 
points resulted from lack of baseline CrT in the medical chart or lack of follow-
up a minimum of 12±2 weeks after the last DeX implant. n represents the total 
number of eyes in each group, and n represents number of eyes with follow-up data 
for analysis; as vision was analyzed after the last injection, patients initially treated 
with DEX implant and received subsequent reinjections may not have had sufficient 
follow-up data in their medical charts for analysis purposes. 
Abbreviations: CrT, central retinal thickness; DeX, intravitreal dexamethasone, 
DMe, diabetic macular edema; rVO, retinal vein occlusion; se, standard error.
??????????????????µ???????????? ????????????????????????µ???????????? ??????????????????µ????????????
??????????????????µ??????????? ????????????????????????µ??????????? ??????????????????µ???????????
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Figure 4 OCT retinal images from representative DMe, BrVO, and uveitis study eyes at baseline and after treatment with the DeX implant. BCVa and CrT by OCT are indicated. 
Abbreviations: BCVa, best-corrected visual acuity; CrT, central retinal thickness; DeX, intravitreal dexamethasone; DMe, diabetic macular edema; BrVO, branch retinal 
vein occlusion; OCT, optical coherence tomography.
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those with DME or RVO) had both a history of steroid 
response and an absolute IOP reading 35 mmHg recorded at 
any follow-up visit after treatment with the DEX implant(s). 
The proportions of DME, RVO, and uveitis eyes with a 
history of steroid response requiring topical IOP-lowering 
medications following treatment with the DEX implant in the 
study were 30.0%, 40.0%, and 62.5%, respectively.
In the uveitis study eye cohort, four eyes had glaucoma 
surgery prior to treatment with the DEX implant. The adverse 
event report revealed that one eye had an IOP increase 
related to DEX implant injection that resolved following 
treatment with topical IOP-lowering medication. Another 
eye had ongoing mild pain deemed by the investigator to be 
unrelated to the DEX implant injection and did not require 
any treatment. The other two uveitis eyes that had undergone 
prior glaucoma surgery did not have any new safety concerns 
following treatment with DEX implant(s) over the duration 
of the study.
In total, 1.7% (2/120) of study eyes receiving the DEX 
implant underwent glaucoma surgery during the study. One 
eye with CRVO and no history of prior steroid response under-
went glaucoma surgery at 2.3 months because the IOP had 
increased from 24 mmHg at baseline to 33 mmHg before the 
surgery, despite ongoing treatment with three IOP-lowering 
medications. One other study eye (not in the DME, RVO, 
or uveitis cohorts) with a history of steroid response had 
glaucoma surgery at 3.4 months because IOP had increased 
by greater than 10 mmHg following DEX implant injection 
Table 5 Treatment-related adverse events occurring in 1% of all patients
System Organ Class/Preferred Term All patients (N=101) DME (n=24) RVO (n=29) Uveitis (n=20)
Patients, 
% (n)
Events, 
n
Patients, 
% (n)
Events, 
n
Patients, 
% (n)
Events, 
n
Patients, 
% (n)
Events, 
n
all adverse events 33.7 (34) 52 33.3 (8) 11 37.9 (11) 16 25.0 (5) 8
investigations
iOP increased 20.8 (21) 31 25.0 (6) 11 27.6 (8) 11 10.0 (2) 2
eye disorders
Cataract subcapsular 2.0 (2) 4 0.0 (0) 0 0.0 (0) 0 5.0 (1) 2
Visual acuity reduced 2.0 (2) 2 0.0 (0) 0 6.9 (2) 2 0.0 (0) 0
injury, poisoning, and procedural complications
retinal detachment 2.0 (2) 3 0.0 (0) 0 0.0 (0) 0 5.0 (1) 1
Abbreviations: DMe, diabetic macular edema; iOP, intraocular pressure; rVO, retinal vein occlusion.
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Figure 5 increase in iOP following treatment with the DeX implant.
Notes: Proportion of study eyes with increases in iOP 10 mmhg compared with 
baseline and absolute iOP readings 25 mmhg and 35 mmhg recorded at any 
follow-up visit after DeX implant injection. Data for the proportion of eyes with iOP 
readings 25 mmhg and 35 mmhg were calculated at any available study visit. 
One eye each in the uveitis and rVO subgroups were not included in the respective 
total available sample sizes for the analysis of iOP increase 10 mmhg because 
of missing baseline iOPs in medical charts. For each group, n represents the total 
number of eyes available for analysis, and n represents the number of study eyes 
with respective increases in iOP. 
Abbreviations: DeX, intravitreal dexamethasone; DMe, diabetic macular edema; 
iOP, intraocular pressure; rVO, retinal vein occlusion.
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Figure 6 The proportion of study eyes requiring use of topical iOP-lowering 
medication(s) at any follow-up visit after DeX implant injection.
Notes: For each group, n represents the total number of eyes available for 
analysis, and n represents the total number of study eyes requiring iOP-lowering 
medication. 
Abbreviations: DeX, intravitreal dexamethasone; DMe, diabetic macular edema; 
iOP, intraocular pressure; rVO, retinal vein occlusion.
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(from 11 mmHg at baseline to 23 mmHg), despite treatment 
with a fixed combination IOP-lowering medication. 
Cataract surgery was performed in 29.8% (14/47) of 
all phakic study eyes receiving at least one DEX implant 
injection over a maximum follow-up period of 19.3 months; 
27.3% (3/11) of DME eyes (two with prior vitrectomy), 
7.7% (1/13) of RVO eyes, and 45.5% (5/11) of uveitis eyes 
had cataract surgery. Almost half of these surgeries (42.9%) 
were performed 5–12 months after starting treatment with 
the DEX implant.
Discussion
The Chart Review of Ozurdex® in Macular Edema 
(CHROME) study reports experience with the DEX implant 
by retina and uveitis specialists in the Canadian clinical 
setting. This study evaluated use of the DEX implant in 
patients with persistent ME secondary to a wide variety of 
conditions. The results of similar studies focusing on specific 
patient populations in other countries have recently been 
published. A large retrospective study was conducted in 
patients with BRVO-related or CRVO-related ME (n=289) 
in the USA who received two or more DEX implant injec-
tions. The patients received a mean of 3.2 (range 2–9) DEX 
implant injections, alone or combined with other therapies, 
and experienced improvements in CRT and visual acuity 
with each subsequent injection.19 In a retrospective study 
conducted in Germany of RVO patients (n=102) receiving 
a single DEX implant injection, significant improvements 
in BCVA and reductions in CRT were observed.18 In other 
ocular indications, a small retrospective study concerning 
noninfectious uveitis (27 patients, 38 study eyes) found that 
repeat DEX implant injections improved retinal thickness and 
resolved inflammation, which resulted in improved ocular 
function.23 Functional and anatomic improvements after DEX 
implant treatment have also been reported in several case 
series evaluating patients with persistent DME.21,22,26
In Canada, the DEX implant was approved for treatment 
of ME secondary to CRVO in 2011 and for treatment of 
noninfectious uveitis affecting the posterior segment of 
the eye in 2012.24 The recent approval for the treatment 
of adult pseudophakic DME granted by Health Canada, 
came in 2015, well after the conclusion of the CHROME 
study. The data presented herein covers a time frame when 
the Canadian experience with the DEX implant was very 
limited. Herein, the most common use of the DEX implant 
was off-label treatment for DME, followed by treatment 
of study eyes with RVO and uveitis, to improve visual 
acuity and to resolve ME, and as rescue therapy for eyes 
unresponsive to other therapies. The fact that almost three- 
quarters of patients had persistent ME for a period of at least 
12 months prior to treatment with the DEX implant sug-
gests DEX implant injections were being used primarily as 
salvage therapy. At the time the study was conducted, with 
the exception of the province of Quebec, the DEX implant 
was not included in government-funded drug formularies 
in Canada, which greatly limited access to the drug and was 
likely an important factor that restricted its earlier use or 
choice as first-line therapy for ME in these patients.
The majority of study eyes had persistent ME despite 
prior treatment and procedures. Subsequent treatment with 
the DEX implant improved visual acuity and ME. In the 
DME subgroup, more than 90% of study eyes had had ME 
for at least 12 months before entering the study. Compared 
with baseline, decreases in CRT were statistically significant 
(P0.0001). However, this anatomic improvement is not 
reflected in a statistically significant improvement in visual 
acuity for the DME cohort. A closer look at our data revealed 
that the improvement in visual acuity was more pronounced 
in pseudophakic eyes than in phakic eyes. These findings 
are in line with results from clinical trials of DEX implant 
injections for the treatment of patients with DME.17 We 
suspect that phakic eyes with DME did not show significant 
visual acuity improvement following treatment with the 
DEX implant because of development of cataracts. Cata-
ract is known to be more prevalent among elderly diabetic 
patients.27 Moreover, in this study, more diabetic patients 
with ME underwent vitrectomy prior to treatment with the 
DEX implant than patients with other pathologies, further 
exacerbating the risk of cataract development.28
Results from two large, randomized, sham-controlled 
Phase III trials (together comprising the Macular Edema 
Assessment of implantable Dexamethasone in diabetes 
or the MEAD study) evaluating the efficacy and safety of 
the DEX implant in patients with DME have recently been 
reported.17 Similar to the CHROME study, patients received 
DEX implant reinjections approximately every 6 months; 
however, in the MEAD study, patients were administered 
up to seven DEX implants over a period of 3 years and no 
concomitant treatments were permitted. In both studies, rates 
of glaucoma surgery were low (0% in CHROME study DME 
eyes; 1.4% in MEAD study eyes), and the proportion of study 
eyes with increased IOP (IOP change 10 mmHg, absolute 
IOPs 25 mmHg or 35 mmHg) was similar. As in the 
current study, treatment with the DEX implant resulted in 
significant improvement in BCVA and CRT compared with 
sham treatment in the MEAD study. However, vision gains 
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
39
 o
n 
21
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1265
real-world assessment of intravitreal DeX implants in Me
following DEX implant reinjections were likely confounded 
by cataract progression in phakic eyes, given that subgroup 
analysis of pseudophakic DME eyes demonstrated consistent 
significant improvements in BCVA relative to sham-treated 
eyes over the 3-year study period.17
Study eyes with uveitis demonstrated the largest gain 
in BCVA (P0.0001) and the highest proportion of eyes 
gaining 1, 2, and 3 lines of vision after treatment with 
the DEX implant in our study. This group of study eyes also 
demonstrated the greatest decreases in CRT (P0.0001) 
following DEX implant injections. These improvements 
occurred often in patients with ME resistant to traditional 
therapy of IVTA and periocular steroid injections.29 The 
uveitis cohort received treatment with the DEX implant 
earlier than other cohorts (56.6% of uveitis study eyes had 
had ME for at least 12 months prior to the DEX implant 
compared with 73.3% of all study eyes). This finding suggests 
the uveitis eyes in the present study had comparatively less 
irreversible damage to retinal structures than the other more 
refractory retinal disease cohorts, which potentially explains 
the improved functional changes. Greater improvements in 
the uveitis subgroup could also be due to the lower BCVA 
(mean logMAR 0.71±0.07; 20/102 Snellen equivalents) and 
greater CRT (517.2±40.3 μm) of these patients at baseline. In 
the Phase III DEX implant RVO study, sham-treated control 
patients who completed the double-masked 180-day phase 
and were eligible (BCVA 84 letters or CRT 250 µm) for 
a delayed first treatment with DEX implant (BCVA) demon-
strated less improvement in BCVA than that seen in patients 
who had their first DEX implant treatment 6 months earlier.13 
These results suggest that delaying treatment may decrease 
the ability of patients with ME to benefit from treatment with 
the DEX implant.
In the present study, eyes with RVO had significant 
improvements in visual acuity and anatomic changes follow-
ing DEX implant injections. RVO patients were most likely 
to have repeat DEX implant injections (50%, 15/30 eyes) and 
to be treated with no concomitant medication or procedure 
other than the DEX implant (73.3%, 22/30 eyes). Our results 
are similar to those of a US-based retrospective study, which 
evaluated the efficacy and safety of two or more DEX implant 
injections for treatment of ME in RVO patients, and reported 
improvements in visual acuity and CRT with each subsequent 
DEX implant injection (administered alone or combined with 
other therapies).19 Sharareh et al recently published a small 
retrospective chart review involving 18 patients with RVO 
who received at least two intravitreal bevacizumab injec-
tions before treatment with the DEX implant.20 The study 
identified two groups of bevacizumab-resistant patients, 
non-responders and partial responders, who had recurrent 
ME despite continued treatment. Both groups responded to 
subsequent DEX implant therapy, with reductions in central 
foveal and cube average thickness and improvements in 
visual acuity. Taken together, these findings suggest that, in 
clinical practice, patients with ME secondary to RVO may 
benefit from treatment with DEX implants, including patients 
with recalcitrant ME after anti-vascular endothelial growth 
factor (VEGF) therapy.
No new safety concerns were observed compared with 
earlier studies,11–14,19 although results from the CHROME 
study are to be viewed cautiously because of their retrospec-
tive nature, thus being limited to safety information captured 
on patient charts included for analysis. The most common 
adverse event was increased IOP reported in 20.8% of 
patients; 22.9% of study eyes had IOP increases 10 mmHg 
from baseline and 17.5% of study eyes required use of 
IOP-lowering medications during the course of the study 
for control of new or worsening IOP following treatment 
with the DEX implant. These results are in line with the 
Phase III trials of the DEX implant where by the end of the 
study period, no more than 24% of RVO and 23% of uveitis 
study eyes required use of IOP-lowering medications fol-
lowing treatment with the DEX implant.12,14 Elevations in 
IOP after the DEX implant were managed using four or less 
topical IOP-lowering medications, where the majority of 
study eyes required the use of just one or two IOP-lowering 
medications. Few study eyes had glaucoma surgery post-
DEX implant. Cataract surgery was performed in 29.8% 
of the 47 phakic eyes evaluated in the study. However, 
it is not possible to attribute this rate strictly to the DEX 
implant, given that lens opacity at baseline and during the 
study was not collected in the medical charts reviewed in 
this retrospective study, and many of the eyes in our study 
received prior and concurrent steroid treatments (IVTA, 
sub-Tenon’s triamcinolone, and systemic prednisone) in 
addition to the DEX implant. Prior vitrectomy was per-
formed in almost half (47.5%, 57/120) of the study eyes 
which, along with repeated DEX implant treatment, may 
have increased cataract development. There were too few 
patients with phakic eyes in the DME (n=3), RVO (n=1), 
and uveitis (none) cohorts that had cataract surgery follow-
ing treatment with the DEX implant to allow a meaning-
ful analysis of vision-related improvements after cataract 
surgery compared with baseline.
Results from the CHROME study provide new data on 
the real-world utilization and effect of the DEX implant 
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across retinal indications in Canada. Since the date of 
final study data collection, reimbursement programs have 
remained the same and DEX implant treatment patterns 
have not significantly changed in the centers involved in 
the present study. Anti-VEGF therapies remain the first-
line option for treatment of retinal disease, but significant 
proportions of patients who either do not respond optimally 
to anti-VEGF therapy or have disease recurrence have the 
need for frequent anti-VEGF injections that can become 
a significant burden. At the time of data collection for the 
CHROME study, bevacizumab treatments were primarily 
captured; however, now we would likely see more use of 
ranibizumab and aflibercept prior to or administered con-
comitantly with DEX implants.
The major limitations of our study are its retrospective 
and open-label design. No standardized assessments were 
defined prior to treatment across the centers, assessment tools 
such as OCT instruments were not normalized, and adverse 
events were limited to those reported on the medical charts. 
Additionally, per patient data collected depended on the 
number of DEX implant injections, frequency of treatment, 
and duration of follow-up. Analyses were limited to include 
data captured in patient medical charts; consequently, some 
assessments such as evaluation of changes in vitreous haze 
could not be assessed.
Nevertheless, DEX implant(s) provided a one-line to 
three-line gain in visual acuity from baseline, along with 
significant CRT improvements across all indications evalu-
ated in this study. No new safety concerns were observed 
with the DEX implant, and increases in IOP, common to 
corticosteroids, were manageable using topical IOP-lowering 
medications. Additional studies will help to further elucidate 
the efficacy and safety of the DEX implant in various patient 
populations in the clinical setting.
Acknowledgments
This study was supported by Allergan Inc., Markham, 
ON, Canada, and is published on behalf of the CHROME 
Study Group. Writing and editorial assistance was provided 
by Kakuri Omari, PhD, of Evidence Scientific Solutions, 
Philadelphia, PA, and was funded by Allergan, Inc., Irvine, 
CA, USA. All authors met the International Committee of 
Medical Journal Editors authorship criteria. Neither honoraria 
nor payments were made for authorship.
Disclosure
W-CL has served as an advisor, consultant, and speaker, 
and has received travel reimbursement from Allergan Inc. 
and Novartis, has served as an advisor and received travel 
reimbursement and institutional grant(s) from Bayer, has 
served as an advisor and speaker for Alcon, and has served 
as a speaker for Bausch & Lomb. DAA has served as a con-
sultant to Bausch & Lomb and Bayer, has served as a speaker 
for Novartis, and received a grant from Allergan Inc. related 
to the study. PY is a consultant for Bayer and has received 
honoraria for speaking and developing educational material, 
and has served as an advisor and speaker for Alcon, Allergan 
Inc., Bausch & Lomb, and Novartis. JCC has served as an 
advisor and consultant to Bayer, and received travel reim-
bursement from Allergan Inc. related to this study. AK has 
served as an advisor to Allergan Inc. DALM has served as 
an advisor to Alcon, Allergan Inc., and Bayer. AO has served 
as a consultant and a speaker, and has received grant(s) from 
Novartis, and has served as a consultant to Allergan Inc. TR 
has served as a consultant and speaker, and received hono-
raria for developing educational material from Alcon, has 
been a speaker for Allergan Inc., and AMO, and has received 
honoraria for developing education material from Bausch & 
Lomb. TGS has served as an advisor to Alcon, Allergan 
Inc., Bayer, and Novartis. ET has served as an advisor and 
consultant to Allergan Inc. LW has served as a consultant to 
Allergan Inc. CS is a statistical consultant to Allergan Inc., 
and DCB is an employee of Allergan Inc.
References
 1. Kleinman ME, Baffi JZ, Ambati J. The multifactorial nature of retinal 
vascular disease. Ophthalmologica. 2010;224 Suppl 1:16–24.
 2. Wolfensberger TJ, Gregor ZJ. Macular edema – rationale for therapy. 
Dev Ophthalmol. 2010;47:49–58.
 3. Sarao V, Veritti D, Boscia F, Lanzetta P. Intravitreal steroids for the treat-
ment of retinal diseases. Scientific World Journal. 2014;2014:989501.
 4. Hardman JG, Limburd LE, Molinoff PB, Ruddon RW, Gilman AG, 
editors. Goodman and Gilman’s: The Pharmacological Basis of Thera-
peutics. 9th ed. New York, NY, USA: McGraw-Hill; 1996.
 5. Kwak HW, D’Amico DJ. Evaluation of the retinal toxicity and 
pharmacokinetics of dexamethasone after intravitreal injection. Arch 
Ophthalmol. 1992;110:259–266.
 6. Maxwell DP Jr, Brent BD, Diamond JG, Wu L. Effect of intravit-
real dexamethasone on ocular histopathology in a rabbit model of 
endophthalmitis. Ophthalmology. 1991;98:1370–1375.
 7. Nabih M, Peyman GA, Tawakol ME, Naguib K. Toxicity of high-dose 
intravitreal dexamethasone. Int Ophthalmol. 1991;15:233–235.
 8. Ozurdex (dexamethasone intravitreal implant 0.7 mg). [Package insert]. 
Irvine, CA, USA. Allergan, Inc.; 2014.
 9. Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation 
of the safety and performance of an applicator for a novel intravitreal 
dexamethasone drug delivery system for the treatment of macular 
edema. Retina. 2009;29:46–51.
 10. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and 
pharmacodynamics of a sustained-release dexamethasone intravitreal 
implant. Invest Ophthalmol Vis Sci. 2011;52:80–86.
 11. Kuppermann BD, Blumenkranz MS, Haller JA, et al. Randomized 
controlled study of an intravitreous dexamethasone drug delivery 
system in patients with persistent macular edema. Arch Ophthalmol. 
2007;125:309–317.
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
39
 o
n 
21
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1267
real-world assessment of intravitreal DeX implants in Me
 12. Haller JA, Bandello F, Belfort R Jr, et al. Randomized, sham-controlled 
trial of dexamethasone intravitreal implant in patients with macular edema 
due to retinal vein occlusion. Ophthalmology. 2010;117:1134–1146.
 13. Haller JA, Bandello F, Belfort R Jr, et al. Dexamethasone intravitreal 
implant in patients with macular edema related to branch or central reti-
nal vein occlusion twelve-month study results. Ophthalmology. 2011; 
118:2453–2460.
 14. Lowder C, Belfort R Jr, Lightman S, et al. Dexamethasone intravitreal 
implant for noninfectious intermediate or posterior uveitis. Arch Oph-
thalmol. 2011;129:545–553.
 15. Boyer DS, Faber D, Gupta S, et al. Dexamethasone intravitreal implant 
for treatment of diabetic macular edema in vitrectomized patients. 
Retina. 2011;31:915–923.
 16. Shaikh AH, Petersen MR, Sisk RA, Foster RE, Riemann CD, Miller DM. 
Comparative effectiveness of the dexamethasone intravitreal implant in 
vitrectomized and non-vitrectomized eyes with macular edema second-
ary to central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 
Retina. 2013;44:28–33.
 17. Boyer DS, Yoon YH, Belfort R Jr, et al. Three-year, randomized, sham-
controlled trial of dexamethasone intravitreal implant in patients with 
diabetic macular edema. Ophthalmology. 2014;121:1904–1914.
 18. Bezatis A, Spital G, Hohn F, et al. Functional and anatomical results 
after a single intravitreal Ozurdex injection in retinal vein occlusion: 
a 6-month follow-up – the SOLO study. Acta Ophthalmol. 2013;91: 
e340–e347.
 19. Capone A Jr, Singer MA, Dodwell DG, et al. Efficacy and safety of 
two or more dexamethasone intravitreal implant injections for treatment 
of macular edema related to retinal vein occlusion (SHASTA study). 
Retina. 2014;34:342–351.
 20. Sharareh B, Gallemore R, Taban M, Onishi S, Wallsh J. Recalcitrant 
macular edema after intravitreal bevacizumab is responsive to an 
intravitreal dexamethasone implant in retinal vein occlusion. Retina. 
2013;33:1227–1231.
 21. Dutra Medeiros M, Postorino M, Navarro R, Garcia-Arumi J, Mateo C, 
Corcostegui B. Dexamethasone intravitreal implant for treatment of 
patients with persistent diabetic macular edema. Ophthalmologica. 
2014;231:141–146.
 22. Zucchiatti I, Lattanzio R, Querques G, et al. Intravitreal dexamethasone 
implant in patients with persistent diabetic macular edema. Ophthal-
mologica. 2012;228:117–122.
 23. Tomkins-Netzer O, Taylor SR, Bar A, et al. Treatment with repeat 
dexamethasone implants results in long-term disease control in eyes 
with noninfectious uveitis. Ophthalmology. 2014;121:1649–1654.
 24. Ozurdex (dexamethasone intravitreal implant 0.7 mg). [Product mono-
graph]. Markham, ON, Canada; Allergan Inc.; 2015.
 25. Holladay JT. Proper method for calculating average visual acuity. 
J Refract Surg. 1997;13:388–391.
 26. Zalewski D, Raczynska D, Raczynska K. Five-month observation of 
persistent diabetic macular edema after intravitreal injection of Ozurdex 
implant. Mediators Inflamm. 2014;2014:364143.
 27. Petrash JM. Aging and age-related diseases of the ocular lens and vitre-
ous body. Invest Ophthalmol Vis Sci. 2013;54:ORSF54–ORSF59.
 28. Bhatnagar P, Schiff WM, Barile GR. Diabetic vitrectomy: the influence 
of lens status upon surgical outcomes. Curr Opin Ophthalmol. 2008; 
19:243–247.
 29. Kruh J, Foster CS. Corticosteroid-sparing agents: conventional systemic 
immunosuppressants. Dev Ophthalmol. 2012;51:29–46.
 
Cl
in
ica
l O
ph
th
al
m
ol
og
y 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
14
7.
8.
23
0.
39
 o
n 
21
-F
eb
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Ophthalmology
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/clinical-ophthalmology-journal
Clinical Ophthalmology is an international, peer-reviewed journal 
covering all subspecialties within ophthalmology. Key topics include: 
Optometry; Visual science; Pharmacology and drug therapy in eye 
diseases; Basic Sciences; Primary and Secondary eye care; Patient 
Safety and Quality of Care Improvements. This journal is indexed on 
PubMed Central and CAS, and is the official journal of The Society of 
Clinical Ophthalmology (SCO). The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.
Clinical Ophthalmology 2015:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1268
lam et al
Supplementary material
Table S1 information collected at each retrospective study visit
Information collected Visit 1
medical historya
Visit 2
injection visitsb
Visit 3
post-injection follow-upc
informed consent (if required by research ethics board) √
Patient demographics √
Patient eligibility √
Medical history/comorbidities √
Current ophthalmic diagnosis √
Duration of macular edema prior to injection √
Ophthalmic medication history √
Past ocular treatment history √
lens status √
Ophthalmoscope examination findings √
Dexamethasone intravitreal implant injection informationd √
Other medication(s) prior to or concomitantly with injection √
Other procedures(s) prior to or concomitantly with injection √
Pre-injection assessmentse √
rationale for repeat injection √
Post-injection assessmentse √
Post-injection medications √
Post-injection proceduresf √
adverse events √ √
Prior and concomitant medications √ √ √
Prior and concomitant procedures √ √ √
study completion or early termination √
Notes:  aPrior to the first injection. bAt the first injection and repeated for each subsequent injection administered. cevery 4±2 weeks after each injection. dinjection information: 
eye(s) treated, date of injection, current retinal disease, rationale for treatment. ePre-injection and post-injection assessments: intraocular pressure, best-corrected visual 
acuity, optical coherence tomography, fluorescein angiography. fPost-injection procedures: laser photocoagulation, ocular surgery, other ocular procedures.
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